Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 228-845-2 | CAS number: 6362-79-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16 July 2012 to 27 September 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: US EPA OPPTS 870.3650, July 2000
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: CrI:WI(Han) (outbred, SPF-Quality)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Refer to Section 7.5.1
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Refer to Section 7.5.1
- Details on mating procedure:
- Females were caged together with males on a one-to-one-basis in Macrolon plastic cages (MIII type, height 18 cm).
Post-mating Males were housed in their home cage (Macrolon plastic cages, MIV type, height 18 cm) with a maximum of 5 animals/cage. Females were individually housed in Macrolon plastic cages (MIII type, height 18 cm).
Following a minimum of 14 days of exposure for the males and females, one female was cohabitated with one male of the same treatment group, avoiding sibling mating. Detection of mating was confirmed by evidence of sperm in the vaginal lavage or by the appearance of an intravaginal copulatory plug. This day was designated Day 0 post-coitum. Once mating occurred, the males and females were separated. A maximum of 14 days was allowed for mating, after which females who had not shown evidence of mating were separated from their males. Detection of mating was not confirmed for animal nos. 43 (Group 1), 58 (Group 2) and 62 (Group 3) which did deliver live offspring. The mating date of these animals were estimated at 21 days prior to the actual delivery dates. These days were designated Day 0 post-coitum.
The females were allowed to litter normally. Day 1 of lactation was defined as the day when a litter was found completed (i.e. membranes and placentas cleaned up, nest build up and/or feeding of pups started). Females that were littering were left undisturbed. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Refer to Section 7.5.1
- Duration of treatment / exposure:
- After acclimatization, four groups of ten male and ten female Wistar Han rats were exposed by oral gavage to the test substance at 0, 100, 300 and 1000 mg/kg/day. Males were exposed for 29 days, i.e. 2 weeks prior to mating, during mating, and up to termination. Females were exposed for 43 - 53 days, i.e. during 2 weeks prior to mating, during mating, during post-coitum, and during at least 4 days of lactation.
- Frequency of treatment:
- Refer to Section 7.5.1
- Details on study schedule:
- Males were exposed for 29 days, i.e. 2 weeks prior to mating, during mating, and up to the day prior to scheduled necropsy. Females were exposed for 43-53 days, i.e. during 2 weeks prior to mating, during mating, during post-coitum, and during at least 4 days of lactation (up to the day prior to scheduled necropsy). Female nos. 41, 43 (Group 1), 62 , 70 (Group 3) and 77 (group 4) were not dosed during littering.
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Low dose group
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Mid dose group
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- High dose group
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- PREPARATION OF DOSING SOLUTIONS:
Formulations (w/w) were prepared daily within 6 hours prior to dosing and were homogenized to a visually acceptable level. No adjustment was made for specific gravity/density of the test substance, vehicle, and/or formulation. No correction was made for the purity/composition of the test substance.
Doses were administered by plastic feeding tube.
Dose volume: 5 mL/kg - Positive control:
- None
- Parental animals: Observations and examinations:
- Male number paired with, mating date, confirmation of pregnancy, and delivery day were recorded. Pregnant females were examined to detect signs of difficult or prolonged parturition, and cage debris of pregnant females was examined to detect signs of abortion or premature birth. Any deficiencies in maternal care (such as inadequate construction or cleaning of the nest, pups left scattered and cold, physical abuse of pups or apparently inadequate lactation or feeding) were examined.
- Oestrous cyclicity (parental animals):
- Not determined
- Sperm parameters (parental animals):
- Parameters examined in selected 5 male parental animals:
testis weight, epididymis weight, prostate weight (after at least 24 h fixation), and weight of seminal vesicles including the coagulating glands
Refer to Section 7.5.1 for all histopathological analyses conducted in this study. - Litter observations:
- Each litter was examined for the following if practicle and possible:
Mortality / Viability
The numbers of live and dead pups on Day 1 of lactation and daily thereafter were determined. If possible, defects or cause of death were evaluated.
Clinical signs
At least once daily, detailed clinical observations were made for all animals.
Body weights
Live pups were weighed on Days 1 and 4 of lactation.
Sex
Sex was determined for all pups on Days 1 and 4 of lactation. - Postmortem examinations (parental animals):
- Refer to Section 7.5.1 of this IUCLID file
- Postmortem examinations (offspring):
- Necropsy
Pups surviving to planned termination were killed by decapitation on Days 5-7 of lactation. All pups were sexed and descriptions of all external abnormalities were recorded. The stomach was examined for the presence of milk. If possible, defects or cause of death were evaluated. - Statistics:
- Refer to Section 7.5.1 of this IUCLID file
- Reproductive indices:
- Mating index (%): No. females mated / No. females paired x 100
Fertility index (%): No. pregnant females / No. of females placed x 100
Conception index (%): No. pregnant females / No. females mated x 100
Gestation index (%): No. females bearing live pups / No. pregnant females x 100
Duration ofgestation: No. days between confirmation of mating and the beginning of parturition. - Offspring viability indices:
- Percentage live males at first litter check.
Percentage live females at first litter check.
Percentage of postnatal loss.
Viability index (%): No. live pups before necropsy / No. of pups born alive x 100 - Clinical signs:
- no effects observed
- Description (incidence and severity):
- Refer to Section 7.5.1 of this IUCLID file
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Refer to Section 7.5.1 of this IUCLID file
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Refer to Section 7.5.1 of this IUCLID file
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Refer to Section 7.5.1 of this IUCLID file
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on a lack of significant reproductive effects measured in the study.
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- A screening study for development and reproduction toxicity was performed according to OECD guideline 422 and GLP principles. No significant reproductive toxicity was noted up to a dose of 1000 mg/kg bw/d. The NOAEL for reproductive toxicity was concluded to be1000 mg/kg bw/day.
- Executive summary:
A screening study for development and reproduction toxicity was performed according to OECD guideline 422 and GLP principles. No reproduction toxicity was observed up to the highest dose level tested (1000 mg/kg bw/day). No treatment-related toxicologically relevant changes were noted in any of the reproductive parameters investigated in this study (i.e. mating, fertility and conception indices, precoital time, and numbers of corpora lutea and implantation sites). The NOAEL for reproductive toxicity was concluded to be1000 mg/kg bw/day.
Reference
Reproductive results:
No reproduction toxicity was observed up to the highest dose level tested (1000 mg/kg). No treatment-related toxicologically relevant changes were noted in any of the reproductive parameters investigated in this study (i.e. mating, fertility and conception indices, precoital time, and numbers of corpora lutea and implantation sites).
No treatment-related changes were noted in any of the remaining developmental parameters investigated in this study (i.e. gestation index and duration, parturition, maternal care and early postnatal pup development consisting of mortality, clinical signs, body weight and macroscopy).
Reproduction data summary
Control | 100 mg/kg | 300 mg/kg | 1000 mg/kg | |
Females paired | 10 | 10 | 10 | 10 |
Females mated | 10 | 9 | 10 | 9 |
Females non-mated | 0 | 1 | 0 | 1 |
Pregnant females | 9 | 9 | 10 | 9 |
Non-pregnant females | 1 | 0 | 0 | 0 |
Females with living pups on Day 1 | 9 | 9 | 10 | 9 |
Mating index (%) | 100.0 | 90.0 | 100.0 | 90.0 |
Fertility index (%) | 90.0 | 90.0 | 100.0 | 90.0 |
Conception index (%) | 90.0 | 100.0 | 100.0 | 100.0 |
Gestation index (%) | 100.0 | 100.0 | 100.0 | 100.0 |
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In an OECD 422 guideline study, the subject material was administered daily by gavage to groups of 10 each male and female rats at dose levels of 0 (control), 100, 300 or 1000 mg/kg bw/day. Males were exposed for 2 weeks prior to mating, during mating, and up to termination (for 28 days). Females were exposed for 2 weeks prior to mating, during mating, during post-coitum, and for at least 4 days of lactation (43 -53 days).
No reproduction toxicity was observed up to the highest dose level tested (1000 mg/kg). No treatment-related toxicologically relevant changes were noted in any of the reproductive parameters investigated in this study (i.e. mating, fertility and conception indices, precoital time, and numbers of corpora lutea and implantation sites).
Short description of key information:
An OECD 422 test (combined repeated dose toxicity with reproductive / developmental toxicity) conducted by oral gavage was conducted on the subject material.
Justification for selection of Effect on fertility via oral route:
Lack of significant reproductive effects were reported in a guideline study (OECD 422).
Effects on developmental toxicity
Description of key information
An OECD 422 test (combined repeated dose toxicity with reproductive / developmental toxicity) conducted by oral gavage was conducted on the subject material.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16 July 2012 to 27 September 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD 422, Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: CrI:WI(Han) (outbred, SPF-Quality)
- Details on test animals or test system and environmental conditions:
- Refer to Section 7.5.1 of this IUCLID file
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Refer to Section 7.5.1 of this IUCLID file
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Refer to Section 7.5.1 of this IUCLID file
- Details on mating procedure:
- Refer to Section 7.5.1 and 7.8.1 of this IUCLID file
- Duration of treatment / exposure:
- Refer to Section 7.5.1 and 7.8.1 of this IUCLID file
- Frequency of treatment:
- Refer to Section 7.5.1 and 7.8.1 of this IUCLID file
- Duration of test:
- Refer to Section 7.5.1 and 7.8.1 of this IUCLID file
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Low dose group
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Mid dose group
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- High dose group
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Refer to Section 7.5.1 and 7.8.1 of this IUCLID file
- Maternal examinations:
- Refer to Section 7.5.1 and 7.8.1 of this IUCLID file
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: No
- Number of late resorptions: No - Fetal examinations:
- Not applicable
- Statistics:
- Refer to Section 7.5.1 and 7.8.1 of this IUCLID file
- Indices:
- Liters (total)
Duration of gestation
Dead pups at first litter check
Living pups at first litter check
Postnatal loss
Viability index (%) - Details on maternal toxic effects:
- Maternal toxic effects:no effects. Remark: Refer to Section 7.5.1 of this IUCLID file
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Key result
- Abnormalities:
- no effects observed
- Reduction in number of live offspring:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Three pups of the control group and one pup at 300 mg/kg were found dead on Day 1 or missing on Day 2 of lactation. Pups missing were most likely cannibalised. No toxicological relevance was attributed to these dead/missing pups since the mortality incidence did not show a dose-related trend and remained within the range considered normal for pups of this age.
- Changes in sex ratio:
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg bw/day, sex ratio of the pups indicated more female than male pups (62% female pups compared to 47% of the control group); this was statistically significantly different from controls. The laboratory’s historical control data (97 screening studies, years 2008-2012) includes two studies in which a comparable percentage of female pups was noted. As these two historical studies show the ultimate limit of the historical control data range, a possible relationship to treatment could not be excluded for the changed sex ratio in the current study. This was strengthened by the fact that seven out of nine litters in this group showed more female than male pups. The change in sex ratio may be indicative of a decrease in anogenital distance for the male pups leading to a ‘misclassification’ into female pups, rather than a direct effect on sex ratio (sexing was done using anogenital distance).
- Changes in litter size and weights:
- no effects observed
- Anogenital distance of all rodent fetuses:
- effects observed, treatment-related
- Description (incidence and severity):
- See remark under "changes in sex ratio". The change in sex ratio may be indicative of a decrease in anogenital distance for the male pups leading to a ‘misclassification’ into female pups, rather than a direct effect on sex ratio.
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Description (incidence and severity):
- At macroscopic examination, no milk in the stomach was noted for three litters of the control group, one litter at 100 mg/kg bw/day and four litters (not all pups) at 300 mg/kg. This was not considered to be treatment related or toxicologically relevant since no dose response relationship was noted, it also occurred in the control group, and these pups survived until the scheduled necropsy, indicating they were all sufficiently fed during lactation. This finding for the animals surviving to the scheduled necropsy is likely secondary to the time when the actual necropsies were performed, and is not attributable to treatment.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- changes in sex ratio
- Key result
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- external: anogenital distance
- Description (incidence and severity):
- A change in sex ratio was observed, which may be indicative of a decrease in anogenital distance for the male pups leading to a ‘misclassification’ into female pups (rather than a direct effect on sex ratio).
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects in the absence of maternal toxicity effects
- Dose response relationship:
- no
- Relevant for humans:
- yes
- Conclusions:
- A screening study for development and reproduction toxicity was performed according to OECD guideline 422 and GLP principles. Developmental toxicity was observed at 1000 mg/kg bw/day as a possible relationship to treatment could not be excluded for the change in sex ratio. The NOAEL for developmental effects was 300 mg/kg bw/day.
- Executive summary:
A screening study for development and reproduction toxicity was performed according to OECD guideline 422 and GLP principles. At 1000 mg/kg, sex ratio of the pups indicated more female than male pups (62% female pups compared to 47% of the control group); this was statistically significantly different from controls. The laboratory’s historical control data (97 screening studies, years 2008-2012) includes two studies in which a comparable percentage of female pups was noted. As these two historical studies show the ultimate limit of the historical control data range, a possible relationship to treatment could not be excluded for the changed sex ratio in the current study. This was strengthened by the fact that seven out of nine litters in this group showed more female than male pups.
It should be noted that this change in sex ratio may be indicative of a decrease in anogenital distance for the male pups leading to a ‘misclassification’ into female pups, rather than a direct effect on sex ratio.
No treatment-related changes were noted in any of the remaining developmental parameters investigated in this study (i.e. gestation index and duration, parturition, maternal care and early postnatal pup development consisting of mortality, clinical signs, body weight and macroscopy).
Reference
Developmental data summary
Control | 100 mg/kg | 300 mg/kg | 1000 mg/kg | |
Litters | ||||
Total | 9 | 9 | 10 | 9 |
Dration of gestation | ||||
Mean | 21.3 | 21.1 | 21.3 | 21.3 |
St Dev | 0.5 | 0.6 | 0.5 | 0.5 |
N | 9 | 9 | 10 | 9 |
Dead pups at first litter check | ||||
Litters affected (%) | 1 | 0 | 0 | 0 |
Total | 1 | 0 | 0 | 0 |
Mean | 0.1 | 0 | 0 | 0 |
St Dev | 0.3 | 0.0 | 0.0 | 0.0 |
N | 9 | 9 | 10 | 9 |
Living pups at first litter check | ||||
% males/%females | 53/47 | 53/47 | 54/46 | 38/62# |
Total | 93 | 104 | 92 | 102 |
Mean | 10.3 | 11.6 | 9.2 | 11.3 |
St Dev | 2.5 | 3.2 | 3.7 | 2.9 |
N | 9 | 9 | 10 | 9 |
Postnatal loss | ||||
% of living pups | 2.2 | 0.0 | 1.1 | 0.0 |
Litters affected (No.) | 1 | 0 | 1 | 0 |
Total (No.) | 2 | 0 | 1 | 0 |
Mean | 0.2 | 0.0 | 0.1 | 0.0 |
St Dev | 0.7 | 0.0 | 0.3 | 0.0 |
N | 9 | 9 | 10 | 9 |
Viability Index (No.) | 97.8 | 100.0 | 98.9 | 100.0 |
# Fischer's exact test significance at 5%
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 300 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In an OECD 422 guideline study, the subject material was administered daily by gavage to groups of 10 each male and female rats at dose levels of 0 (control), 100, 300 or 1000 mg/kg bw/day. Males were exposed for 2 weeks prior to mating, during mating, and up to termination (for 28 days). Females were exposed for 2 weeks prior to mating, during mating, during post-coitum, and for at least 4 days of lactation (43 -53 days).
At 1000 mg/kg, the sex ratio of the pups indicated more female than male pups (62% female pups compared to 47% of the control group); this was statistically significantly different from controls. The laboratory’s historical control data (97 screening studies, years 2008-2012) includes two studies in which a comparable percentage of female pups was noted. As these two historical studies show the ultimate limit of the historical control data range, a possible relationship to treatment could not be excluded for the changed sex ratio in the current study. This was strengthened by the fact that seven out of nine litters in this group showed more female than male pups.
It should be noted that this change in sex ratio may be indicative of a decrease in anogenital distance for the male pups leading to a ‘misclassification’ into female pups, rather than a direct effect on the sex ratio.
No treatment-related changes were noted in any of the remaining developmental parameters investigated in this study (i.e. gestation index and duration, parturition, maternal care and early postnatal pup development consisting of mortality, clinical signs, body weight and macroscopy).
Justification for selection of Effect on developmental toxicity: via oral route:
Significant developmental effects were reported in a guideline study (OECD 422).
Justification for classification or non-classification
Based on a lack of significant reproductive effects noted in an OECD 422 study in rats, no classification of the test material for reproductive effects is warranted.
Based on significant developmental effects noted in an OECD 422 study in rats, the subject material receives a classification under the EU Dangerous Substance Directive (67/548/EEC) of Repr. Cat. 3; R63 (Possible risk of harm to the unborn child). Classification under the EU Regulation 1272/2008 results in a Repr. Cat. 2 (H361: Suspected of damaging fertility or the unborn child).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.